z-logo
open-access-imgOpen Access
Antihypertensive drug combinations
Author(s) -
Jeong Bae Park
Publication year - 2014
Publication title -
journal of korean medical association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.199
H-Index - 15
eISSN - 2093-5951
pISSN - 1975-8456
DOI - 10.5124/jkma.2014.57.3.253
Subject(s) - medicine , drug , antihypertensive drug , blood pressure , pharmacology , calcium channel blocker , clinical trial , intensive care medicine
. - , . 60 , , - , , - , , . A (angiotensin receptor blocker, angiotensin converting enzyme inhibitor), B (betablocker), C (calcium channel blocker), D (diuretics) 4 [1]. 1/3 [2-4]. [5,6]. . [5], [7] Hypertension has a diverse pathophysiology. Theoretically, one drug is not sufficient to control high blood pressure (BP) in most hypertension. Therefore, the combination of two or more drugs with different mechanisms is needed to meet the target BP. In setting the target BP, a low-dose combination of two drugs with different mechanisms has greater efficacy and safety than a higher dose of one drug. Recent clinical trials and hypertension guidelines from different parts of the world report that the combination of renin-angiotensin system inhibitors with calcium channel antagonists or diuretics is generally recommended but combinations including beta-blockers, rarely so. However, if even a combination of three drugs all with different mechanisms, each at full dose does not control the BP, then a betablocker and/or other antihypertensive drug should be considered. Rarely, an interventional procedure such as renal sympathetic denervation has been applied, but evidence supporting such therapies remains limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom